Alphamab Oncology (FRA:3NK) Gross Property, Plant and Equipment: €90.61 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3NK Alphamab Oncology FRA:3NK
55 GF Score
Price €0.88
GF Value €0.82
! 4 Warning Signs
View Full Analysis

What is Alphamab Oncology Gross Property, Plant and Equipment?

Alphamab Oncology FRA:3NK +0.57% 55 Gross Property, Plant and Equipment is €90.61 Mil as of Dec. 2025. GuruFocus rates FRA:3NK with a GF Score™ of 55/100 and a GF Value™ of €0.82. The stock has 4 warning signs investors should review.

Alphamab Oncology's quarterly gross PPE declined from Dec. 2024 (€94.16 Mil) to Jun. 2025 (€63.08 Mil) but then increased from Jun. 2025 (€63.08 Mil) to Dec. 2025 (€90.61 Mil).

Alphamab Oncology's annual gross PPE increased from Dec. 2023 (€90.19 Mil) to Dec. 2024 (€94.16 Mil) but then declined from Dec. 2024 (€94.16 Mil) to Dec. 2025 (€90.61 Mil).


Alphamab Oncology  (FRA:3NK) Gross Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Alphamab Oncology Gross Property, Plant and Equipment Related Terms


Alphamab Oncology Gross Property, Plant and Equipment Historical Data

* Premium members only.

The historical data trend for Alphamab Oncology's Gross Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology Gross Property, Plant and Equipment Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Gross Property, Plant and Equipment
Get a 7-Day Free Trial Premium Member Only 79.55 93.43 90.19 94.16 90.61

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Gross Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.19 70.06 94.16 63.08 90.61
FRA:3NK
55GF Score
Alphamab Oncology FRA:3NK
Gross Property, Plant and Equipment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alphamab Oncology Gross Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.

What does a Gross Property, Plant and Equipment of €90.61 Mil mean?
Alphamab Oncology (FRA:3NK) has a Gross Property, Plant and Equipment of €90.61 Mil as of Dec. 2025. The total gross property, plant and equipment assets recorded on a company's balance sheet. View historical data on Alphamab Oncology and its competitors.
Is Alphamab Oncology's Gross Property, Plant and Equipment too high?
Alphamab Oncology's current Gross Property, Plant and Equipment is €90.61 Mil. Overall, Alphamab Oncology has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Gross Property, Plant and Equipment compare to VRTX and REGN?
Alphamab Oncology's Gross Property, Plant and Equipment of €90.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Property, Plant and Equipment for a Biotechnology company?
A good Gross Property, Plant and Equipment depends on the Biotechnology industry context. However, Gross Property, Plant and Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Property, Plant and Equipment mean?
A high Gross Property, Plant and Equipment can signal that a stock is expensive relative to its fundamentals. The total gross property, plant and equipment assets recorded on a company's balance sheet. View historical data on Alphamab Oncology and its competitors. Alphamab Oncology's current Gross Property, Plant and Equipment is €90.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Alphamab Oncology (FRA:3NK) has a current Gross Property, Plant and Equipment of €90.61 Mil. The stock's GF Value™ is €0.82, compared to a current price of €0.88 — trading 7.3% above its estimated fair value. The current Gross Property, Plant and Equipment is €90.61 Mil. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Property, Plant and Equipment calculated?
Gross Property, Plant and Equipment is calculated from a company's financial statements. For Alphamab Oncology (FRA:3NK), the current Gross Property, Plant and Equipment is €90.61 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alphamab Oncology (FRA:3NK) Overvalued in 2026?

Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued. The current stock price of €0.88 is trading 7.3% above its estimated GF Value™ of €0.82.

Key valuation signals for FRA:3NK:

  • Gross Property, Plant and Equipment: €90.61 Mil
  • GF Value™: €0.82 vs. price of €0.88 (7.3% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the FRA:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alphamab Oncology Business Description

Other Exchanges 09966:Hong Kong3NK:Germany
Address No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score

Get the complete analysis for FRA:3NK

Gross Property, Plant and Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.88
Price
€0.82
GF Value